This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically signif...
Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral agents...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
This is an open access article distributed under the Creative Commons Attribution License which perm...
This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) ...
This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) ...
Hepatitis C virus (HCV) is considered to be the leading cause of hepatocellular carcinoma (HCC). Dur...
The Hepatitis C virus (HCV) infection is a public health problem. The high level of HCV replication ...
The presence of resistance-associated substitutions (RASs) at NS5A region might compromise the effic...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromis...
Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral agents...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
This is an open access article distributed under the Creative Commons Attribution License which perm...
This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) ...
This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) ...
Hepatitis C virus (HCV) is considered to be the leading cause of hepatocellular carcinoma (HCC). Dur...
The Hepatitis C virus (HCV) infection is a public health problem. The high level of HCV replication ...
The presence of resistance-associated substitutions (RASs) at NS5A region might compromise the effic...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromis...
Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral agents...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...
BACKGROUND: The efficacy of NS5A inhibitors for the treatment of patients chronically infected with ...